Allegra

Allegra is an allergy-relief medicine brand marketed primarily for consumers seeking relief from allergic rhinitis and related symptoms. Its principal active ingredient is fexofenadine, a second-generation antihistamine commonly used to relieve sneezing, runny nose, itchy nose or throat, and itchy or watery eyes. Compared with some older antihistamines, fexofenadine is generally positioned as less likely to cause drowsiness, although effects and precautions depend on the formulation, the user’s condition, and local labeling. In the United States and some other markets, Allegra products are sold over the counter and include adult formulations, children’s products, and selected products aimed at nasal or eye symptoms. The brand is currently part of Sanofi’s consumer-health business. Product names, formulations, dosages, and marketing authorization holders can vary by country, so local packaging and regulatory labeling should be consulted. Allegra is a consumer healthcare brand for antihistamine medicines whose active ingredient is fexofenadine. The product is used primarily to relieve symptoms associated with seasonal or perennial allergic rhinitis, including sneezing, nasal discharge, itchy nose, and itchy or watery eyes, and in some markets for chronic urticaria, commonly known as hives. Depending on the jurisdiction and product presentation, Allegra may be sold as a prescription medicine, an over-the-counter medicine, or in both forms. The brand is closely associated with fexofenadine, a second-generation antihistamine developed as a successor to terfenadine. Fexofenadine selectively blocks peripheral H1 histamine receptors and is generally positioned as a non-sedating or less-sedating alternative to older antihistamines. The medicine is commonly offered in tablet, orally disintegrating, liquid, or other market-specific formulations, with strengths and labeling determined by local regulators. Product claims, age indications, dosing instructions, and availability vary by country and should not be generalized across markets. Allegra has had a multinational commercial history. In the United States and several other markets, the brand has been associated with Sanofi's consumer healthcare business. In Japan, Allegra products have been marketed by Shionogi under local commercial arrangements, including products containing fexofenadine for allergic conditions. The same brand name can therefore refer to locally authorized products with different packaging, dosage forms, legal classifications, and marketing organizations. The brand's principal positioning is symptom relief without the pronounced drowsiness traditionally associated with some first-generation antihistamines. This positioning has made Allegra prominent in the self-care allergy category, where it competes with other oral antihistamine brands and with intranasal corticosteroids, eye drops, decongestants, and non-drug measures. Its competitive relevance depends on efficacy, perceived alertness, duration of action, price, dosage convenience, regulatory status, and the strength of local distribution. As a medicine brand, Allegra is subject to country-specific pharmacovigilance, advertising, labeling, and recall requirements. Consumers may encounter different formulations marketed under related names, such as products emphasizing 12-hour or 24-hour relief, combination products, or pediatric preparations. Such variants cannot be treated as interchangeable without reference to their local labels. No single global corporate owner, launch date, or product portfolio is asserted here because those details differ by market and are not established by the supplied source material. Allegra is a consumer healthcare brand for antihistamine medicines whose active ingredient is fexofenadine, a second-generation antihistamine developed as a successor to terfenadine. The product is used primarily to relieve symptoms associated with seasonal or perennial allergic rhinitis, including sneezing, nasal discharge, itchy nose, and itchy or watery eyes, and in some markets for chronic urticaria, commonly known as hives. Fexofenadine selectively blocks peripheral H1 histamine receptors and is generally positioned as a non-sedating or less-sedating alternative to older antihistamines. Depending on the jurisdiction and product presentation, Allegra may be sold as a prescription medicine, an over-the-counter medicine, or in both forms, and is commonly offered in tablet, orally disintegrating, liquid, or other market-specific formulations, with strengths and labeling determined by local regulators. In the United States and several other markets, the brand has been associated with Sanofi's consumer healthcare business; in Japan, Allegra products have been marketed by Shionogi under local commercial arrangements. The same brand name can therefore refer to locally authorized products with different packaging, dosage forms, legal classifications, and marketing organizations. Product claims, age indications, dosing instructions, and availability vary by country and should not be generalized across markets.

Allegra is an allergy-medicine brand centered on fexofenadine. Fexofenadine is the active metabolite of terfenadine and was developed in the context of seeking an antihistamine with less sedation and improved cardiac-safety characteristics than certain earlier products. Allegra subsequently developed primarily as an over-the-counter brand in the United States and other markets, offering products for adults and children and, in selected formulations, products containing a decongestant or aimed at nasal and eye symptoms. The brand later became part of Sanofi’s consumer-health portfolio. Approval dates, formulations, product names, and brand-rights arrangements differ across countries, so its international history cannot be reduced to one uniform timeline. The supplied material is insufficient to verify the brand’s first launch year or particular acquisition and licensing milestones, so unverified dates and financial figures are omitted. Allegra developed as a commercial brand for fexofenadine, a second-generation antihistamine intended to provide histamine-related symptom relief with less central nervous system sedation than many earlier antihistamines. Fexofenadine itself is the active metabolite of terfenadine, and its development formed part of the pharmaceutical industry's effort to retain antihistamine efficacy while reducing safety concerns associated with older compounds. The brand subsequently became part of the international allergy-medicine market. Regulatory classifications have not been uniform: in some countries fexofenadine products were introduced or maintained as prescription medicines, while in others they became available over the counter. This transition enabled Allegra to move from a physician-directed treatment into a widely recognized self-care brand, while also increasing the importance of consumer labeling, responsible advertising, and pharmacovigilance. Commercial control and distribution have varied by territory. Sanofi has been associated with Allegra in a number of international consumer-healthcare markets, while Shionogi has marketed Allegra products in Japan. Local licensing, distribution, and regulatory arrangements mean that the brand's ownership, product assortment, packaging, and approved uses cannot be inferred solely from its presence in another country. The brand's portfolio has generally centered on fexofenadine in multiple dosage forms and strengths. Depending on local authorization, products may address seasonal allergic rhinitis, perennial allergic rhinitis, urticaria, or pediatric use. Some markets have also used distinct product variants and duration-of-action claims. These differences are material: a product sold in one market may not have the same dose, legal status, age restriction, or approved indication as a similarly named product elsewhere. Allegra's long-term market position has been shaped by the continuing demand for allergy treatment, the shift toward nonprescription self-care, competition from other second-generation antihistamines, and the availability of non-oral treatments. The brand remains active, but a complete chronology of its launch dates, corporate transactions, campaigns, executives, and country-specific regulatory events requires market-level primary sources. Allegra's long-term market position has been shaped by the continuing demand for allergy treatment, the shift toward nonprescription self-care, competition from other second-generation antihistamines and from intranasal corticosteroids, eye drops, decongestants, and non-drug measures. The brand remains active, but a complete chronology of its launch dates, corporate transactions, campaigns, executives, and country-specific regulatory events requires market-level primary sources. The supplied material is insufficient to verify the brand's first launch year or particular acquisition and licensing milestones, so unverified dates and financial figures are omitted.

An over-the-counter antihistamine brand positioned as a second-generation antihistamine that relieves allergy symptoms with less drowsiness, with formulations and indications varying by market.

• Antihistamine

  Allegra Allergy

  Allegra's core allergy-relief line uses fexofenadine as its principal active ingredient and is intended for symptoms associated with seasonal and perennial allergies. Common formulations include tablets, while dosage and age indications vary by market and version.

• Antihistamine and decongestant combination

  Allegra-D

  Allegra-D is a combination line pairing an antihistamine with a decongestant, intended for allergy symptoms accompanied by nasal congestion. Decongestants may carry additional contraindications and restrictions, so local labeling or professional advice should be followed.

• oral antihistamine

  Allegra fexofenadine tablets

  Tablet products containing fexofenadine are the core Allegra format in many markets. They are intended to relieve histamine-related symptoms such as sneezing, runny nose, itchy nose, and itchy or watery eyes, and may also be authorized for urticaria. Strengths, dosing frequency, age eligibility, prescription status, and approved claims vary by country.

• oral antihistamine

  Allegra orally disintegrating tablets

  Orally disintegrating or melt-in-the-mouth Allegra products are designed for consumers who prefer a dosage form that can be taken without swallowing a conventional tablet. They contain fexofenadine in a market-specific formulation. Availability, flavoring, dose, storage requirements, and instructions are determined by local authorization and labeling.

• pediatric antihistamine

  Allegra liquid and pediatric formulations

  Liquid or pediatric Allegra formulations are intended for age groups and dosing situations in which a liquid medicine may be more practical than a tablet. They are not globally uniform: concentration, measuring instructions, minimum age, indication, and prescription or over-the-counter status differ by jurisdiction. Use should follow the applicable local product information.